Screener
ARS Pharmaceuticals, Inc. SPRY Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$62.34M-38.9% | -$60.62M-78.6% | -$41.32M-183% | -$51.15M-167% | -$44.88M-259% | ||
| $416K+49.1% | $397K+41.8% | $417K+1,338% | $391K+1,762% | $279K+1,450% | ||
| $928K+39.8% | $7.42M+40.1% | $5.74M+34.6% | $5.69M+58.4% | $664K-80.3% | ||
| -$60.93M-53.9% | -$44.95M-10.3% | -$43.49M-204% | -$47.05M-225% | -$39.59M-444% | ||
| $0-100% | $0-100% | $0-100% | $197K+40.7% | $51K+34.2% | ||
| $41.57M-14.4% | $27.79M-4.4% | $24.11M+124% | —— | $48.57M+484% | ||
| $3.2M+18.5% | $159K-78.1% | $1.13M-98.4% | $100.05M+14,613% | $2.7M+395% | ||
| -$16.16M-238% | -$17M-55.2% | -$18.24M— | $8.02M— | $11.68M+160% | ||
| -$60.93M-53.7% | -$44.95M-10.1% | -$43.49M-204% | -$47.24M-223% | -$39.64M-442% |
FAQ
- How much cash does ARS Pharmaceuticals, Inc. generate?
- ARS Pharmaceuticals, Inc. (SPRY) generated -$196.4M in operating cash flow over the trailing twelve months.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- After $197.0K of capital expenditures, ARS Pharmaceuticals, Inc.'s free cash flow was -$196.6M over the trailing twelve months, down 268.3% year over year.
- Where does ARS Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
